Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins-Reference-Cited by-同舟云学术

Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins

Published:2008-10-08 Issue:21 Volume:51 Page:6902-6915
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Park Cheol-Min¹,Bruncko Milan¹,Adickes Jessica¹,Bauch Joy¹,Ding Hong¹,Kunzer Aaron¹,Marsh Kennan C.¹,Nimmer Paul¹,Shoemaker Alexander R.¹,Song Xiaohong¹,Tahir Stephen K.¹,Tse Christin¹,Wang Xilu¹,Wendt Michael D.¹,Yang Xiufen¹,Zhang Haichao¹,Fesik Stephen W.¹,Rosenberg Saul H.¹,Elmore Steven W.¹

Affiliation:

1. Cancer Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm800669s

Reference40 articles.

1. Bcl-2-regulated apoptosis: mechanism and therapeutic potential

2. The BCL-2 protein family: opposing activities that mediate cell death

3. How the Bcl-2 family of proteins interact to regulate apoptosis

Cited by 263 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Know your molecule: pharmacological characterization of drug candidates to enhance efficacy and reduce late-stage attrition;Nature Reviews Drug Discovery;2024-06-18

2. Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2;Journal of Medicinal Chemistry;2024-05-02

3. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B‐cell lymphoma‐2 inhibitor;Clinical and Translational Science;2024-05

4. Identification of a novel form of caspase-independent cell death triggered by BH3-mimetics in diffuse large B-cell lymphoma cell lines;Cell Death & Disease;2024-04-15

5. Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs;Pharmaceuticals;2024-04-12